ERBB2 and breast cancer: Further to these findings, a short time interval between initial BC diagnosis and metastatic dissemination was also reported to be an independent predictor of BCBM progression, in two studies involving unselected BC patients (effect estimate range: 0.99 – 2.972) [29, 53] and in one study considering solely HER-2 positive patients [23].